Clinical trials: Neoplasms, Metastatic
Breast Neoplasms
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants…
- Trial name
- NCT02756364
- Testing
- Fulvestrant, Sapanisertib
- Where
- 53 sites in United States, Spain
- Volunteers
- 141 people
- Sponsor
- Calithera Biosciences, Inc
Non-Small Cell Lung Cancer, Anemia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
- Trial name
- NCT00858364
- Testing
- Darbepoetin alfa
- Where
- 566 sites in United States, Argentina and 35 more
- Volunteers
- 2,549 people
- Sponsor
- Amgen
Advanced/Metastatic Cervical Cancer
Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure
Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
- Trial name
- CABOCOL-01 (NCT04205799)
- Testing
- Cabozantinib
- Where
- 8 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Francois Baclesse
Stage III Breast Cancer, Stage IIIA Breast Cancer
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
This phase I/II trial studies the side effects and best dose of idasanutlin when given together with atezolizumab, and to see how well atezolizumab and cobimetinib or idasanutlin work in treating participants with stage IV…
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT03566485
- Testing
- Atezolizumab, Cobimetinib, Idasanutlin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
The objective of this study is to improve the chemotherapy decision making process for Latinos with advanced gastrointestinal cancers.
- Conditions
- Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT03602885
- Testing
- Usual chemotherapy education (CE), Chemotherapy education intervention (CEI)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Renal Cell
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
This study is to assess sorafenib as second treatment for patients that have previously received only sunitinib as first-line treatment for advanced renal cell cancer, and who either responded and then progressed with sunitinib…
- Trial name
- NCT00678288
- Testing
- Sorafenib (Nexavar, BAY43-9006), Sorafenib (Nexavar, BAY43-9006) + Interferon
- Where
- 35 sites in Austria, France and 5 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Melanoma
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
- Trial name
- NCT03743766
- Testing
- Relatlimab, Nivolumab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- John Kirkwood
Metastatic Renal Cell Carcinoma
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
To assess whether daily treatment with RAD001 could slow the growth and spread of metastatic carcinoma of the kidney. The safety of RAD001 was also to be studied in this trial.
- Trial name
- RECORD-1 (NCT00410124)
- Testing
- RAD001
- Where
- 93 sites in United States, Australia and 8 more
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer
The goal of this clinical research study is to evaluate the effectiveness of Avastin® in combination with docetaxel and carboplatin in the treatment of lung cancer. The safety of this combination will also be studied.
- Trial name
- NCT00271505
- Testing
- Bevacizumab (Avastin), Carboplatin, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small-Cell Lung Cancer
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer.
- Trial name
- NCT00363766
- Testing
- LY573636-sodium
- Where
- 7 sites in Germany, Italy
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bone Metastases, Cancer Survivor
Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases
This randomized pilot trial studies telemonitoring after surgery to preserve limb function in optimizing mobility in cancer survivors with cancer spread to the bone.
- Conditions
- Bone Metastases, Cancer Survivor, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT02715856
- Testing
- Monitoring Device, Physical Activity Measurement, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Neoplasm
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Primary Objectives: Part 1 To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in participants with advanced solid tumors.
- Trial name
- NCT04418661
- Testing
- Vociprotafib, Pembrolizumab, Adagrasib
- Where
- 20 sites in United States, Argentina and 5 more
- Volunteers
- 65 people
- Sponsor
- Sanofi
Pancreatic Cancer
Cabozantinib and Pembrolizumab in Metastatic Pancreas
This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.
- Trial name
- NCT05052723
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Joseph Kim
Metastatic Breast Cancer
Capecitabine With Digoxin for Metastatic Breast Cancer
To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
- Trial name
- NCT01887288
- Testing
- Capecitabine, Digoxin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Western Regional Medical Center
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Postmenopausal Women, Locally Advanced Metastatic Breast Cancer
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
This was a multi-center, Israeli phase II open label study evaluating treatment with RAD001 (10 mg daily) combined with letrozole (2.5 mg daily) in postmenopausal women after recurrence or progression on Tamoxifen, Anastrozole or…
- Conditions
- Postmenopausal Women, Locally Advanced Metastatic Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT01231659
- Testing
- Everolimus, Letrozole
- Where
- 7 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Carcinoma, Hepatocellular
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with previously treated selected solid tumors, and to determine the recommended Phase 2…
- Conditions
- Melanoma, Carcinoma, Hepatocellular, Colorectal Neoplasms
- Trial name
- NCT05091346
- Testing
- E7386, Pembrolizumab, Lenvatinib
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 89 people
- Sponsor
- Eisai Inc.